Clinical Characteristics, Co-Mutations, and Prognostic Factors of TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Clinical Laboratory · 2026
DOI: 10.7754/clin.lab.2025.250835 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Laboratory, 2026. Verfasst von Xiaoqin Xin und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Mutation, Tumor Suppressor Protein p53.
Abstract (Originalsprache)
BACKGROUND: TP53 mutations confer poor prognosis and heterogeneous clinical features in myeloid neoplasms, but distinguishing factors between AML and MDS and independent prognostic markers within this high-risk group remain unclear. METHODS: This retrospective study evaluated 45 adult patients with TP53-mutated acute myeloid leukemia (AML; n = 22) or myelodysplastic syndromes (MDS; n = 23) treated at Ganzhou People's Hospital between 2018 and 2023. Clinical, laboratory, cytogenetic, and targeted next-generation sequencing data were collected at diagnosis. Sixteen genes frequently mutated in myeloid malignancies were assessed for co-mutation patterns. Progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier and Cox regression; variables with univariate p < 0.10 entered multivariate models. RESULTS: MDS patients were older than AML patients (65.5 ± 9.0 vs. 56.0 ± 15.1 years; p = 0.013), and exhibited lower bone marrow blast percentages (5.6% vs. 49.5%; p < 0.001), while AML cases had higher peripheral WBC counts (8.6 × 10⁹ vs. 2.9 × 10⁹/L; p = 0.002). DNMT3A and TET2 co-mutations were most frequent (15.6% each); FLT3-ITD was enriched in AML (18.2% vs. 0%; p = 0.049). In multivariate analysis, allogeneic HSCT (HR = 0.08; p = 0.022), higher RBC count (HR = 0.39; p = 0.011), hemoglobin (HR = 0.98; p = 0.043), and albumin (HR = 0.91; p = 0.010) independently predicted superior PFS, whereas RUNX1 co-mutation (HR = 18.15; p = 0.028) and lower ALT (HR = 0.97; p = 0.018) were independently associated with OS. CONCLUSIONS: Distinct clinical and molecular features differentiate TP53-mutated AML from MDS. Allogeneic HSCT confers marked survival benefit, and RUNX1 co-mutation identifies an ultra-high-risk subset. Early trans-plant evaluation combined with comprehensive genomic profiling is recommended to guide personalized treatment in this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Xin, X., Li, Y., & Li, X. (2026). Clinical Characteristics, Co-Mutations, and Prognostic Factors of TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clinical Laboratory. https://doi.org/10.7754/clin.lab.2025.250835
Vancouver
Xin X, Li Y, Li X. Clinical Characteristics, Co-Mutations, and Prognostic Factors of TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clinical Laboratory. 2026. doi:10.7754/clin.lab.2025.250835
BibTeX
@article{Xin2026,
author = {Xin, Xiaoqin and Li, Yanhong and Li, Xiaoyu},
title = {Clinical Characteristics, Co-Mutations, and Prognostic Factors of TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndrome},
journal = {Clinical Laboratory},
year = {2026},
doi = {10.7754/clin.lab.2025.250835}
}
EUVIMED